Maryland Board of Pharmacy Public Board Meeting

Agenda December 19, 2018

Name	Title	Present	Absent
Ashby, D.	Commissioner		
Bouyoukas, E	Commissioner		
Evans, K.	Commissioner		
Hardesty, J.	Commissioner/Treasurer		
Laws Jr, A.	Commissioner		
Leikach, N.	Commissioner		
Morgan, K.	Commissioner/President		
Oliver, B	Commissioner		
Peters, R.	Commissioner		
Rusinko, K.	Commissioner		
Toney, R.	Commissioner/Secretary		
Yankellow, E.	Commissioner		
Bethman, L.	Board Counsel		
Felter, B.	Staff Attorney		
Speights-Napata, D.	Executive Director		
Fields, E.	Deputy Director / Operations		1
Evans, T.	Compliance Director		
Brand, E.	Licensing, Legislation and Regulations Manager		
Chew, C.	Management Associate		
	ő		
I. Executive A.) K. Morga			
Committee Board	item on the agenda are advised to notify the Board at this t	time or	
Report(s) President	when the issue is addressed in the agenda.		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		1. Call to Order	
		2. Sign-in Introduction and of meeting attendees – (Please indicate on sign-in sheet if you are requesting CE Units for attendance)	
		3. Distribution of Agenda and packet materials	
	B.) R. Toney, Secretary	4. Review and approve November 2018 Public Meeting Minutes	
II. A. Executive Director Report	D. Speights- Napata,	1. Operations Updates	
	Executive Director	2. Meetings Update	
		I. Pharmacy School Committee Meeting ReportDeena and Steve B.	
		II. New Staff Update:	
		1. Investigation Supervisor: Donna Goldberg	
		2. Inspector: Michelle Taylor	
		3. Licensing Secretary: Fredica Waller	
		III.Rehabilitation Services Update	
		IV.Office Closings: December 25th and January 1st	
		V. State of Maryland Inclement Weather Policy	
B. Operations	E. Fields,	1. Procurement and Budget Updates	
	Deputy Dimension/	a: November 2018 Financial Statements	
	Director/ Operations	2. Management Information Systems (MIS) Unit Updates	
	Operations	a: Systems Automation Enhanced Services	
C. Licensing	E. Brand,	1. Unit Updates	
	Licensing, Legislation and	2. Monthly Statistics	
	Regulations		
	Manager		

Subject	Responsible Party			Discussion			Action Due Date (Assigned To)
		License Type	New	Renewed	Reinstated	Total	
		Distributor	16	0	0	1,323	
		Pharmacy	14	0	0	2,030	
		Pharmacist	67	440	0	12,036	
		Vaccination	36	9	0	4,681	
		Pharmacy Intern - Graduate	2	0	0	44	
		Pharmacy Intern - Student	11	16	0	899	
		Pharmacy Technician	114	293	4	9,805	
		Pharmacy Technician- Student	8	0	0	21	
		TOTAL	268	758	4	38,839	
D. Compliance	T. Evans, Compliance Director	1. Unit Upd 2. Monthly	Statistics	1	1		
		Complaints & Inv		S:			
		• HIPPA V	iolation - 1				

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		 Applicant - 1 Sterile Compounding - 1 Customer Service Issues - 1 Failure to Report to PDMP - 1 Employee Pilferage - 3 Dispensing Error - 3 Refusal to Fill - 4 Unprofessional Conduct - 4 Medication Error - 4 Disciplinary Actions in Another State - 8 Inspection Issues - 13 Invalid/Expired CPR - 15 Resolved (Including Carryover) - 55 Actions within Goal - 44/55 Final disciplinary actions taken - 16 Inspections: Total - 118 Annual Inspections -107 Opening Inspections -8 Closing Inspections -1 Relocation/Change of Ownership Inspections -2 	
E. Legislation & Regulations	E. Brand, Legislation and Regulations Manager	Proposed COMAR 10.34.05.05 Security Responsibilities Proposed COMAR 10.34.32.03 D Requirements to Administer Vaccinations	
		Proposed COMAR 10.34.30 Applications	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		Proposed COMAR 10.34.09 Fees	
		Legislation	
		Generic Substitution Revision 12-504	
III. Committee Reports		Contraceptive Forms	
A. Practice Committee	R. Peters, Chair	Nicholas Ladikos Follow up questions: Just to be clear, we are looking for guidance on three specific, interrelated items for pharmacist-driven penicillin allergy skin testing in an acute care hospital.	
		1. Can a pharmacist obtain written consent by the patient?	
		2. Can a pharmacist administer the full scope of the test, and its three parts, i.e., scratch test, intradermal test, and oral test?	
		3. Can a pharmacist interpret and take action on the results of each part of the test? Proposed response:	
		Even with the patient's consent, the proposed functions you have outlined are not within the scope of practice for a pharmacist. Please be advised that some of these functions may be permissible under a Drug Therapy Management Agreement and Protocol with an authorized prescriber in accordance with §12-6A, Health Occupations Article, Annotated Code of Maryland.	
		If the Board approves the response, Linda will clear it with OAH.	
		William Rollow Question: I am a Maryland-licensed physician. In our practice have had occasion to certify patients for medical cannabis on the	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		mmcc.health.maryland.gov website, often for pain. Would certification of a pharmacist for medical	
		Proposed response:	
		Under Health Gen. 13-3313 and 13-3314, the Board of Pharmacy may not take action against the pharmacist for being a certified patient or possessing a legal 30-day supply of medical cannabis. However, the Board could take action if the pharmacist was found to be practicing pharmacy while under the influence of cannabis.	
		Board of Pharmacy At the Board meeting on November 21, 2018, the Board asked the Practice Committee to draft a policy statement on CBD products that contained more guidance than a referral to the DEA guidelines.	
		Proposed policy statement:	
		The DEA classifies CBD as a Schedule I substance regardless of conflicting state law. At this time, the Board is unable to provide additional guidance regarding this issue.	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
B. Licensing Committee	D. Ashby, Chair	1. Review of Pharmacist Applications: a. MZ- This individual has not filed an application. He wants to earn intern hours in order to get his pharmacist license. He has passed the FPGEE, but does not have the certification. In addition, he is requesting that the Board waive some intern hours based on work experience as a Board-	
		certified Pharmacotherapy specialist (BSPS) with nine-years experience in a hospital (Joint Commission Accredited) and direct patient care outside of the USA. Licensing Committee's Recommendation: Deny b. #115896- The applicant is requesting approval to	
		re-take the MPJE exam for the 6 th time. <u>Licensing Committee's Recommendation:</u> <u>Approve</u>	
		c. #114877- The applicant's application expired on 11/2/2018. She passed the MPJE exam on 11/21/2018. The applicant is requesting an extension of her MDBOP application. It will help her relocate with her husband, who is working at the US Coast Guard station in Washington, DC. <u>Licensing Committee's Recommendation:</u> <u>Approve</u>	
		d. #115206- The applicant is requesting an extension of his MDBOP application which will expire on 12/06/2018. The applicant states that his father passed in May 2018 and that he had to travel to Ghana for his funeral. He stayed in Ghana for 4 months for the funeral and to visit family. This stressful situation impeded his progress to prepare for the exams prior to scheduled deadlines. The	

Page 7 December 19, 2018

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
Subject	Tarty	applicant would like to take the exams in January 2019. Licensing Committee's Recommendation: Approve a 6-month extension e. #118733- The applicant is requesting the Board grant her permission to re-take the MPJE for the 6 th time. In the alternative, she is requesting that the Board accept her previous MPJE score of 78 from 04/04/2016. Licensing Committee's Recommendation: Approve to retake the MPJE for the 6 th time;	(Assigned 10)
		deny request to accept the MPJE score of 78 from 4/4/2016 f. #115169- The applicant is requesting approval to re-take the NAPLEX exam for an 8 th time. Licensing Committee's Recommendation: Approve to retake the NAPLEX exam for the 8 th time	
		g. #118788- The applicant is requesting approval to re-take the NAPLEX exam for the 7 th time. Licensing Committee's Recommendation: Approve to retake the NAPLEX exam for the 7 th time	
		h. JK-CE request <u>Licensing Committee's Recommendation: Deny</u> <u>because the course is not sufficiently related to</u> <u>the practice of pharmacy</u>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		 a. AD- The intern is requesting an extension/renewal of his intern license which expires on 12/31/2018. Until September, he was unable to earn intern hours because he was working fulltime as Associate Professor in Pharmaceutical Science. As of September 2018 he started earning internship hours working in a pharmacy. In December, he registered as a pharmacy technician. Licensing Committee's Recommendation: Approve an extension for one year and terminate his Pharmacy Technician license 3. Review of Pharmacy Technician Applications: a. DD- The applicant began the Technician Training program in August 2018. She is requesting an extension as she is recovering from emergency surgery that she had in October. The applicant does not expect to return to the pharmacy until February 2019. She expects she will need an additional 2-3 months to complete her program. Licensing Committee's Recommendation: Approve a 6-month extension 	
		4. Review of Distributor Applications: 5. Povious of Phormacy Applications:	
		 a. #P07853-Pharmacy is requesting a refund of the pharmacy renewal fee of \$500. The renewal fee was paid on 05/05/2018 under P07853. An ownership change occurred on 10/2018 and the pharmacy had to pay \$700. Licensing Committee's Recommendation: Deny 	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		 6. Review of Pharmacy Technicians Training Programs: a. New Destiny Health Career Center <u>Licensing Committee's Recommendation:</u> <u>Approve</u> b. Jarrettsville Pharmacy Update to Program <u>Licensing Committee's Recommendation:</u> <u>Approve</u> 7. New Business: 	
C. Public Relations Committee	E. Yankellow, Chair	Public Relations Committee Update:	
D. Disciplinary	J. Hardesty, Chair	Disciplinary Committee Update	
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update	
IV. Other Business & FYI	K. Morgan, President		
V. Adjournment	K. Morgan, President	A. The Public Meeting was adjourned. B. K. Morgan convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications. C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan convened an Administrative Session for purposes of discussing confidential disciplinary cases.	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.	